Abnova’s COVID-19 Viral Antigen Rapid Test is a rapid 15 minutes chromatographic immunoassay for detection of SARS nucleocapsid antigens in the nasal swab specimens taken from patients suspected of COVID-19 within the first 5 days of symptom onset.
The test detects but does not differentiate between SARS-CoV and SARS-CoV-2 viruses.
When the nasal swab specimens are processed by the extraction buffer and added to the Sample Zone, the SARS nucleocapsid antigens present in the specimens bind to the antibodies conjugated to the nanoparticles in the test strip.
The antigen-conjugate complexes migrate across the test strip to the Result Zone and are capture by a line of antibodies bound on the membrane.
The test is intended to be visually interpreted. A positive result is determined by a visible colored line at the Test “T” position and the Control “C” on the test strip.
A negative result is determined by the absence of a visible colored line at the Test “T” position and the presence of a visible colored line at the Control “C” on the test strip.
Control line must appear every time to ensure the quality of the sample processing.
Abnova’s COVID-19 Viral Antigen Rapid Test is validated for use for direct specimen testing without transport media. – Read IFU for more information.